Crossmark

Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma

Crossref DOI link: https://doi.org/10.1186/s40478-018-0583-4

Published Online: 2018-08-21

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ronellenfitsch, Michael W. http://orcid.org/0000-0002-1402-6290
Zeiner, Pia S.

Mittelbronn, Michel

Urban, Hans

Pietsch, Torsten

Reuter, Dirk

Senft, Christian

Steinbach, Joachim P.

Westphal, Manfred

Harter, Patrick N. http://orcid.org/0000-0001-5530-6910
License Information

Text and Data Mining valid from 2018-08-21
More Information

Article History

Received: 10 August 2018

Accepted: 10 August 2018

First Online: 21 August 2018

Competing interests

: MWR, JPS and PNH received a grant to purchase materials necessary for immunohistochemistry from Oncoscience, the pharmaceutical company that owns nimotuzumab. DR is an employee and managing director of Oncoscience.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.